Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 501

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Insulin Resistance and Cardiovascular Disease1

McFarlane, Samy I., Banerji, Maryann, Sowers, James R. · 2001 · The Journal of Clinical Endocrinology & Metabolism

Abstract

INSULIN RESISTANCE describes an impaired biological response to insulin (1–4). In the early states of insulin resistance there is a compensatory increase in insulin concentrations. Although hyperinsulinemia may compensate for resistance to some biological actions of insulin, it may result in overexpression of actions in tissues that retain normal or minimally impaired sensitivity to insulin. Also, high concentrations of insulin can act through receptors for insulin-like growth factor I (IGF-I) (5–8). Thus, accentuation of some actions of insulin with concurrent resistance to other actions gives rise to diverse clinical manifestations and sequelae of the insulin resistance syndrome. In general, insulin resistance can be due to a prereceptor, receptor, or postreceptor abnormality (1). One signaling pathway for insulin and IGF-I is the phosphatidylinositide 3-kinase (PI3 -kinase) system. Upon binding to their receptors, there is autophosphorylation of the β-subunit, which mediates noncovalent but stable interactions between the receptor and cellular proteins (1). Several proteins are then rapidly phosphorylated on tyrosine residues by ligand-bound insulin receptors, including insulin receptor substrate-1 (IRS-1) (1). IRS docking proteins bind strongly to the enzyme PI3 -kinase (1), a heterodimer consisting of a p85 regulatory subunit and a p110 catalytic subunit, via SH-2 domain interaction with the p85 subunit (1). Insulin and IGF-I stimulation increases the amount of PI3 -kinase associated with IRS, and the binding process is associated with increased activity of the enzyme. Activation of the enzyme is crucial for transducing the actions of these peptides in cardiovascular (CV) tissue (9–14) as well as conventional insulin-sensitive tissues (1). The interruption of this pathway creates a resistance to the actions of insulin/IGF-I in stimulating vascular nitric oxide (NO) production (9, 10), CV cation transport mechanisms (11, 12–15), as well as glucose transport (1, 6) (Fig. 1) in classically sensitive tissues such as muscle and adipose tissue. PI3-kinase mediates the increases in NO, Na+ pump, K+ channel, and calcium (Ca2+) myofilament sensitivity by increasing the trafficking and translocation of NO synthase and cation pump units as well as glucose transporters (1, 9, 16) (Fig. 2). Therefore, resistance to the actions of insulin and IGF-I in these tissues occurs whenever there is reduced PI3 -kinase activation (Fig. 2). The actions of insulin and IGF-I on cation metabolism and vascular tone. The actions of insulin and IGF-I on cation metabolism and vascular tone. The interactions of insulin/IGF-I and the RAS in cardiovascular tissue (−) indicates insulin/IGF-I signaling steps that are inhibited by Ang II. The interactions of insulin/IGF-I and the RAS in cardiovascular tissue (−) indicates insulin/IGF-I signaling steps that are inhibited by Ang II. Evidence has been garnered indicating that insulin resistance and the resultant hyperinsulinemia are causally related to hypertension (Table 2). First, untreated essential hypertensive patients have higher fasting and postprandial insulin levels than normotensive subjects regardless of body mass; a direct correlation between plasma insulin concentrations and blood pressure levels exists (17, 18). Second insulin resistance and hyperinsulinemia exist in rats with genetic hypertension such as the Dahl hypertensive (19), the spontaneously hypertensive (20), and the Zucker obese hypertensive rat strain (21). Finally, the relationship between insulin and hypertension seen in essential hypertension does not occur with secondary hypertension (20, 22). Accordingly, insulin resistance and hyperinsulinemia are not consequences of hypertension, but, instead, a genetic predistribution may contribute to both disorders. This concept is supported by the finding of altered glucose metabolism in normotensive offspring of hypertensive persons (22–24). Mechanisms for the development of hypertension in insulin resistance/hyperinsulinemia include activation of the sympathetic nervous system, renal sodium retention, altered transmembrane cation transport, growth-promoting effects of vascular smooth muscle cells, and vascular hyperreactivity (1–3). Cardiovascular risk factors that cluster with microalbuminuria Cardiovascular risk factors that cluster with microalbuminuria Four large prospective studies (25–28) have shown that hyperinsulinemia is a predictor of coronary artery disease (CAD), with a few prospective reports not demonstrating such a relationship. The greatest association of hyperinsulinemia with CAD has been found in Finland in a population with a very high frequency of CAD (25). Results of a prospective investigation of 2103 men from Quebec (29) clearly showed that high fasting insulin concentrations are an independent predictor of CAD. This important study used an insulin assay without cross-reactivity with proinsulin, thus avoiding that confounding influence. Several rec

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jcem.86.2.7202

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 1999, Hypertension in type II diabetes: update on therapy., J Clin Hypertens, 1, 41

Cited by

See all 501

Metadata

Authors
McFarlane, S. I., Banerji, M., & Sowers, J. R.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2001-02-01
Volume
86
Issue
2
Pages
713-718
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2051181865
Cited by
501
References
68
FWCI
19.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.